Compare Novo Nordisk A/S (NVO) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Star Bulk Carriers Corp — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while Star Bulk Carriers Corp trades at $27.79 (market cap $3.09B). The key difference: Novo Nordisk A/S is far larger — about 67.3× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.79%). Which is the better fit depends on your goals.
| NVO | SBLK | |
|---|---|---|
Market Cap | $207.85B | $3.09B |
Sector | Health | Industrials |
52-Week High | $63.98 | $29.15 |
52-Week Low | $35.29 | $16.79 |
Enterprise Value | $222.55B | $3.77B |
Dividend Yield | 3.81% | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Star Bulk Carriers (SBLK) trades at $27.81, down 2.15% on the day, but maintains a bullish technical outlook with strong support at $27. Fundamentally, the company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Revenue growth accelerated to $1.2 billion in 2026, driving a net margin of 23.86%. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though operations remain unaffected.
The outlook for SBLK is positive, supported by strong profitability, a healthy balance sheet with a debt-to-asset ratio of 27.84%, and a shareholder-friendly dividend policy. Risks include exposure to volatile dry bulk shipping rates and competitive pressures. Analyst consensus is bullish with 58.34% buy ratings, indicating confidence in continued earnings momentum and valuation appeal at a P/E of 10.85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
